237 results
6-K
EX-1
BLRX
Bioline Rx Ltd
30 May 24
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to
7:16am
for autologous transplantation in multiple myeloma patients; whether access to APHEXDA is achieved in a commercially viable manner and whether APHEXDA … property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for and ability to access sufficient
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
for our therapeutic candidates, and the timing of other regulatory filings and approvals;
whether access to APHEXDA is achieved in a commercially viable … ;
estimates of our expenses, future revenues, capital requirements and our need for and ability to access sufficient additional financing, including
6-K
EX-99.1
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
operations, as currently planned, into 2025
Conference Call and Webcast Information
To access the conference call, please dial +1-888-281-1167 from … uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; whether access
6-K
EX-99
BLRX
Bioline Rx Ltd
24 May 24
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial
7:05am
for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; whether access to APHEXDA is achieved … for and ability to access sufficient additional financing, including any unexpected costs or delays in the commercial launch of APHEXDA; risks
6-K
EX-99
BLRX
Bioline Rx Ltd
17 May 24
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
5:07pm
patients; whether access to APHEXDA is achieved in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party … expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs
6-K
EX-99
r827ar8y9mwznr zde
6 May 24
Current report (foreign)
7:14am
6-K
EX-99.1
laqlbe fgg4jetkgq
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
6-K
EX-99
k98k9k10l fb
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
6-K
EX-10.1
gtjf5g1
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
6-K
EX-99.1
emgtykouaqi s6d2
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
424B5
wr0fl3jsu
1 Apr 24
Prospectus supplement for primary offering
10:30am
20-F/A
mu11 ok66wsww
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
ji0b34ag7jsxj3eynz
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
nwrax7zm
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
EX-99
z3yuqa3mrmkwqw9
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
ezedhjzjx qm146jtt
16 Feb 24
Current report (foreign)
7:07am
F-3
kkxnvlxk
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
kb4tg1tc2wcj73 lrc
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am